請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/48090
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 王錦堂 | |
dc.contributor.author | Yi-Ting Tsai | en |
dc.contributor.author | 蔡依廷 | zh_TW |
dc.date.accessioned | 2021-06-15T06:46:00Z | - |
dc.date.available | 2021-12-31 | |
dc.date.copyright | 2012-03-02 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-06-23 | |
dc.identifier.citation | 1. Murray PR, American Society for Microbiology.: Manual of clinical microbiology, 7th edn. Washington, D.C.: ASM Press; 1999.
2. Chang FY, Chou MY, Fan RL, Shaio MF: A clinical study of Klebsiella liver abscess. Taiwan Yi Xue Hui Za Zhi 1988, 87(3):282-287. 3. Chang FY, Chou MY: Comparison of pyogenic liver abscesses caused by Klebsiella pneumoniae and non-K. pneumoniae pathogens. J Formos Med Assoc 1995, 94(5):232-237. 4. Wang JH, Liu YC, Lee SS, Yen MY, Chen YS, Wann SR, Lin HH: Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis 1998, 26(6):1434-1438. 5. Chou FF, Kou HK: Endogenous endophthalmitis associated with pyogenic hepatic abscess. J Am Coll Surg 1996, 182(1):33-36. 6. Chang SC, Fang CT, Hsueh PR, Chen YC, Luh KT: Klebsiella pneumoniae isolates causing liver abscess in Taiwan. Diagn Microbiol Infect Dis 2000, 37(4):279-284. 7. Tsai FC, Huang YT, Chang LY, Wang JT: Pyogenic liver abscess as endemic disease, Taiwan. Emerg Infect Dis 2008, 14(10):1592-1600. 8. Chee SP, Ang CL: Endogenous Klebsiella endophthalmitis--a case series. Ann Acad Med Singapore 1995, 24(3):473-478. 9. Lindstrom ST, Healey PR, Chen SC: Metastatic septic endophthalmitis complicating pyogenic liver abscess caused by Klebsiella pneumoniae. Aust N Z J Med 1997, 27(1):77-78. 10. Yeoh KG, Yap I, Wong ST, Wee A, Guan R, Kang JY: Tropical liver abscess. Postgrad Med J 1997, 73(856):89-92. 11. Hidaka T, Yokota T, Tamura K: [A case of liver abscess associated with endophthalmitis caused by Klebsiella pneumoniae]. Kansenshogaku Zasshi 1993, 67(1):76-80. 12. Higashi T, Makino Y, Katsurada K: [A case of gas-containing liver abscess with multiple metastatic lesions]. Kansenshogaku Zasshi 1995, 69(9):1017-1020. 13. Naito T, Kawakami T, Tsuda M, Ebe T, Sekiya S, Isonuma H, Matsumoto T, Watanabe K: [A case of endophthalmitis and abscesses in the liver and the lung caused by Klebsiella pneumoniae]. Kansenshogaku Zasshi 1999, 73(9):935-938. 14. Dylewski JS, Dylewski I: Necrotizing fasciitis with Klebsiella liver abscess. Clin Infect Dis 1998, 27(6):1561-1562. 15. Aguilar J, Cruz A, Ortega C: [Multiple hepatic and pulmonary abscesses caused by Klebsiella pneumoniae]. Enferm Infecc Microbiol Clin 1994, 12(5):270-271. 16. Cahill M, Chang B, Murray A: Bilateral endogenous bacterial endophthalmitis associated with pyogenic hepatic abscess. Br J Ophthalmol 2000, 84(12):1436. 17. Saccente M: Klebsiella pneumoniae liver abscess, endophthalmitis, and meningitis in a man with newly recognized diabetes mellitus. Clin Infect Dis 1999, 29(6):1570-1571. 18. Han SHB: Review of Hepatic-Abscess from Klebsiella-Pneumoniae - an Association with Diabetes-Mellitus and Septic Endophthalmitis. Western Journal of Medicine 1995, 162(3):220-224. 19. Kauffmann F: On the Serology of the Klebsiella Group. Acta Pathologica Et Microbiologica Scandinavica 1949, 26(3):381-406. 20. Mizuta K, Ohta M, Mori M, Hasegawa T, Nakashima I, Kato N: Virulence for Mice of Klebsiella Strains Belonging to the 01-Group - Relationship to Their Capsular (K) Types. Infection and Immunity 1983, 40(1):56-61. 21. Fung CP, Hu BS, Chang FY, Lee SC, Kuo BIT, Ho MT, Siu LK, Liu CY: A 5-year study of the seroepidemiology of Klebsiella pneumoniae: High prevalence of capsular serotype K1 in Taiwan and implication for vaccine efficacy. Journal of Infectious Diseases 2000, 181(6):2075-2079. 22. Pan YJ, Fang HC, Yang HC, Lin TL, Hsieh PF, Tsai FC, Keynan Y, Wang JT: Capsular polysaccharide synthesis regions in Klebsiella pneumoniae serotype K57 and a new capsular serotype. J Clin Microbiol 2008, 46(7):2231-2240. 23. Chaves J, Ladona MG, Segura C, Coira A, Reig R, Ampurdanes C: SHV-1 beta-lactamase is mainly a chromosomally encoded species-specific enzyme in Klebsiella pneumoniae. Antimicrob Agents Chemother 2001, 45(10):2856-2861. 24. Haeggman S, Lofdahl S, Burman LG: An allelic variant of the chromosomal gene for class A beta-lactamase K2, specific for Klebsiella pneumoniae, is the ancestor of SHV-1. Antimicrob Agents Chemother 1997, 41(12):2705-2709. 25. Yan JJ, Wu SM, Tsai SH, Wu JJ, Su IJ: Prevalence of SHV-12 among clinical isolates of Klebsiella pneumoniae producing extended-spectrum beta-lactamases and identification of a novel AmpC enzyme (CMY-8) in Southern Taiwan. Antimicrob Agents Chemother 2000, 44(6):1438-1442. 26. Yu WL, Pfaller MA, Winokur PL, Jones RN: Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan. Emerg Infect Dis 2002, 8(5):522-524. 27. Bradford PA: Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001, 14(4):933-951, table of contents. 28. Fircanis S, McKay M: Recognition and management of extended spectrum beta lactamase producing organisms (ESBL). Med Health R I 2010, 93(5):161-162. 29. Yu WL, Chuang YC, Walther-Rasmussen J: Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control. J Microbiol Immunol Infect 2006, 39(4):264-277. 30. Yan JJ, Hsueh PR, Lu JJ, Chang FY, Shyr JM, Wan JH, Liu YC, Chuang YC, Yang YC, Tsao SM et al: Extended-spectrum beta-lactamases and plasmid-mediated AmpC enzymes among clinical isolates of Escherichia coli and Klebsiella pneumoniae from seven medical centers in Taiwan. Antimicrob Agents Chemother 2006, 50(5):1861-1864. 31. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR: Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009, 53(12):5046-5054. 32. Hsueh PR, Wu JJ, Teng LJ, Chen YC, Yang PC, Ho SW, Luh KT: Primary liver abscess caused by one clone of Klebsiella pneumoniae with two colonial morphotypes and resistotypes. Emerg Infect Dis 2002, 8(1):100-102. 33. 方啟泰: 造成肝膿瘍之侵襲性克雷伯氏肺炎桿菌菌株致病基因的研究. 臨床醫學研究所 博士論文 2002:16-17. 34. 鄭德齡: Klebsiella pneumonia 肝膿瘍 : 臺灣地區的特產. J Infect Dis Soc ROC 1997, 1:1-3. 35. Cheng DL, Liu YC, Yen MY, Liu CY, Shi FW, Wang LS: Pyogenic liver abscess: clinical manifestations and value of percutaneous catheter drainage treatment. J Formos Med Assoc 1990, 89(7):571-576. 36. Cherubin CE, Eng RH: Experience with the use of cefotaxime in the treatment of bacterial meningitis. Am J Med 1986, 80(3):398-404. 37. Fang CT, Chen YC, Chang SC, Sau WY, Luh KT: Klebsiella pneumoniae meningitis: timing of antimicrobial therapy and prognosis. QJM 2000, 93(1):45-53. 38. Tsai SS, Huang JC, Chen ST, Sun JH, Wang CC, Lin SF, Hsu BR, Lin JD, Huang SY, Huang YY: Characteristics of Klebsiella pneumoniae bacteremia in community-acquired and nosocomial infections in diabetic patients. Chang Gung Med J 2010, 33(5):532-539. 39. Smith HW, Huggins MB: Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982, 128(2):307-318. 40. Levin BR, Bull JJ: Phage therapy revisited: The population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. American Naturalist 1996, 147(6):881-898. 41. Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Reed E, Ding L, Gong J et al: Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med 2006, 17(2):309-317. 42. Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen Y, Jin Z, Fujimoto S, Nasimuzzaman MD et al: Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 2003, 187(4):613-624. 43. McVay CS, Velasquez M, Fralick JA: Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 2007, 51(6):1934-1938. 44. Chhibber S, Kaur S, Kumari S: Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J Med Microbiol 2008, 57(Pt 12):1508-1513. 45. Olczak M, Strumillo B: [Phage therapy of staphylococcal infections of the skin.]. Pol Tyg Lek 1961, 16:250-252. 46. Slopek S, Durlakowa I, Weber-Dabrowska B, Kucharewicz-Krukowska A, Dabrowski M, Bisikiewicz R: Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch Immunol Ther Exp (Warsz) 1983, 31(3):267-291. 47. Slopek S, Durlakowa I, Weber-Dabrowska B, Kucharewicz-Krukowska A, Dabrowski M, Bisikiewicz R: Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evaluation of the results. Arch Immunol Ther Exp (Warsz) 1983, 31(3):293-327. 48. Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M: Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections. Arch Immunol Ther Exp (Warsz) 1985, 33(2):261-273. 49. Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M: Results of bacteriophage treatment of suppurative bacterial infections. V. Evaluation of the results obtained in children. Arch Immunol Ther Exp (Warsz) 1985, 33(2):241-259. 50. Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M: Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of the results obtained in 370 cases. Arch Immunol Ther Exp (Warsz) 1985, 33(2):219-240. 51. Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A: Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp (Warsz) 1987, 35(5):569-583. 52. Weber-Dabrowska B, Mulczyk M, Gorski A: Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplant Proc 2003, 35(4):1385-1386. 53. Weber-Dabrowska B, Mulczyk M, Gorski A: Bacteriophage therapy of bacterial infections: an update of our institute's experience. Arch Immunol Ther Exp (Warsz) 2000, 48(6):547-551. 54. Fang CT, Chuang YP, Shun CT, Chang SC, Wang JT: A novel virulence gene in Klebsiella pneumoniae strains causing primary liver abscess and septic metastatic complications. J Exp Med 2004, 199(5):697-705. 55. Chou HC, Lee CZ, Ma LC, Fang CT, Chang SC, Wang JT: Isolation of a chromosomal region of Klebsiella pneumoniae associated with allantoin metabolism and liver infection. Infection and Immunity 2004, 72(7):3783-3792. 56. Ma LC, Fang CT, Lee CZ, Shun CT, Wang JT: Genomic heterogeneity in Klebsiella pneumoniae strains is associated with primary pyogenic liver abscess and metastatic infection. J Infect Dis 2005, 192(1):117-128. 57. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L et al: Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009, 4(3):e4944. 58. Malik R, Chhibber S: Protection with bacteriophage KO1 against fatal Klebsiella pneumoniae-induced burn wound infection in mice. J Microbiol Immunol Infect 2009, 42(2):134-140. 59. Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S: Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 1996, 93(8):3188-3192. 60. Schluederberg SA, Marshall B, Tachibana C, Levy SB: Recovery frequency of phages lambda and M13 from human and animal faeces. Nature 1980, 283(5749):792-794. 61. Hung CH, Kuo CF, Wang CH, Wu CM, Tsao N: Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob Agents Chemother 2011, 55(4):1358-1365. 62. Kucharewicz-Krukowska A, Slopek S: Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz) 1987, 35(5):553-561. 63. Kutateladze M, Adamia R: Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 2010, 28(12):591-595. 64. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CR: Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 2002, 70(1):204-210. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/48090 | - |
dc.description.abstract | 克雷白氏肺炎桿菌造成的社區性化膿性肝膿瘍是全球性的新興感染症。目前已知其致病力與莢膜型具有密切關連,莢膜血清分型研究顯示K1與K2二種分型菌株在台灣為最常見的致病菌株。根據報導,台灣10-20% 的院內感染菌株具有extended spectrum β-lactamase (ESBL)抗藥性基因,對第三代頭孢子素產生抗性,近來發現的NDM-1抗藥型基因則可分解廣效型抗生素carbapenem,在治療上造成極大的困擾。噬菌體療法自1930年代已在東歐及前蘇聯用於人類感染疾病的治療至今,但仍有許多限制性及爭議性,此方法便逐漸沒落。近年來細菌抗藥性問題日益嚴重,噬菌體療法重新成為具有潛力的治療方法。由於噬菌體可隨著克雷白氏肺炎桿菌的存在而增生,並具有專一性,因此本研究希望了解噬菌體療法是否具有清除克雷白氏肺炎桿菌深部聚集以達到治療感染之潛力。目前本實驗室已分離可涵蓋所有莢膜型的噬菌體,其中NTUH-K2044-K1-1能夠特異性感染K1莢膜型並具有全基因定序,因此先以此噬菌體評估噬菌體療法。首先純化出低內毒素汙染噬菌體並證實對小鼠不具毒性。藥物動力學結果發現,噬菌體進入小鼠體內6小時在各組織達到最高濃度,在脾臟停留時間最長,也發現噬菌體可通過血腦屏障。免疫反應研究則發現噬菌體進入體內24小時後,血中TNF-α及IL-6的濃度無顯著改變,但小鼠經過重複給予噬菌體卻發現體內清除速率卻顯著提高。以腹腔注射感染克雷白氏肺炎桿菌的小鼠在感染16小時或24小時後,接受單劑噬菌體 (108 PFU)療法可提高75 %存活率。進一步以動物核磁共振造影 (animal MRI)系統確認小鼠發病後,再驗證噬菌體治療的效果。目前完成8隻治療組,4隻對照組觀察顯示,在發病後連續兩週一天給予二次噬菌體 (108 PFU),可延長小鼠帄均壽命。這些結果顯示噬菌體療法可能可用為抗藥性細菌或深部感染之替代或輔助治療。 | zh_TW |
dc.description.abstract | Community-acquired pyogenic liver abscess (PLA) caused by Klebsiella pneumoniae has become an emerging infectious disease. Capsular serotypes K1 and K2 are predominant virulent strains of isolates in Taiwan. Phage therapy has several limitations before, but now it is one of potential therapeutic approaches due to antibiotic resistance. The phage has infection specificity and can be propagated in the presence of its host. Therefore, we evaluated the therapeutic potential of phage in PLA mice model. NTUH-K2044-K1-1 with full genome sequenced was chosen from different phage isolates covering all capsular types to do the pioneer study, which specifically infects K1 strains. Toxicity testing in animals revealed no rectal temperature rise. Pharmacokinetic analysis showed phage concentration reached its peak among different tissues at 6 h and retention of phage in spleen was still observed at 72 h. Moreover, phage potentially crossed blood-brain barrier. The level of TNF- The level of TNF-α and IL-6 in serum beared no difference after phage administration, however, the clearance rates among tissues significantly increased after repeated administrations. Intraperitoneal administration of a single dose of 108 PFU phage at 16 h or 24 h after intraperitoneal K. pneumonia infection was sufficient to improve 75% survival. The efficacy of phage therapy was evaluated in mice with image-documented abscess observed by animal MRI. The results of 8 phage-treated mice and 4 untreated mice illustrated that administration of 108 PFU phage twice a day for 2 weeks could prolong the life span of infected mice. These data suggested that phage therapy have the potential to become alternative or adjuvant agents in treating antibiotic-resistant or deep tissue infections. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T06:46:00Z (GMT). No. of bitstreams: 1 ntu-100-R98445106-1.pdf: 1735898 bytes, checksum: 4ad5bf241574083262e81b8f1e5542a4 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 口試委員審定書………………………………………………………………………I
誌謝……………………………………………………………………………………II 中文摘要………………………………………………………………………………III 英文摘要……………………………………………………………...………………IV 第一章、緒論 1.1 原發性克雷白氏肺炎桿菌肝膿瘍:全球性的新興感染症……………………1 1.2 克雷白氏肺炎桿菌菌株對抗生素的感受性…………………………………1 1.3 克雷白氏肺炎桿菌原發性肝膿瘍及腦膜炎的抗生素治療…………………3 1.4 抗藥性克雷白氏肺炎桿菌感染的抗生素治療………………………………4 1.5 噬菌體簡介……………………………………………………………………4 1.6 噬菌體療法……………………………………………………………………5 1.7 噬菌體療法動物實驗文獻回顧………………………………………………6 1.8 噬菌體療法人體試驗文獻回顧………………………………………………6 1.9 研究動機………………………………………………………………………7 第二章、材料與方法 2.1 實驗菌株………………………………………………………………………8 2.2 培養基…………………………………………………………………………8 2.3 尋找及分離噬菌體……………………………………………………………8 2.4 塗點試驗………………………………………………………………………9 2.5 噬菌體增生……………………………………………………………………9 2.6 噬菌體溶菌斑效價分析………………………………………………………9 2.7 純化低內毒素汙染的噬菌體NTUH-K2044-K1-1……………………………10 2.8 動物實驗 ……………………………………………………………………11 2.9 動物毒性試驗…………………………………………………………………11 2.10 酵素連結免疫吸附法(ELISA) 測量小鼠血清中IL-6及TNF-α 濃度……11 2.11 噬菌體在小鼠體內分布及存在情況分析……………………………………12 2.12 動物致病模式…………………………………………………………………12 2.13以噬菌體療法治療動物感染模式……………………………………………13 第三章、結果 3.1 純化減少內毒素汙染的K1莢膜型噬菌體 (NTUH-K2044-K1-1) …………14 3.2 動物安全性試驗………………………………………………………………14 3.3 噬菌體在體內分布與存在情況分析…………………………………………14 3.4 噬菌體NTUH-K2044-K1-1的致免疫性分析…………………………………15 3.5 初步評估噬菌體療法的有效性………………………………………………15 3.6 利用動物用核磁共振影像系統(animal MRI)結合小鼠感染克雷白氏肺炎桿菌株NTUH-K2044模型偵測並治療早期化膿性肝膿瘍………………………..16 3.7 測定抗藥性克雷伯氏肺炎桿菌感染BALB/c小鼠的半致死劑量 (LD50)…….17 3.8 噬菌體療法對於BALB/c小鼠感染抗藥性克雷伯氏肺炎桿菌之療效……….17 第四章、討論…………………………………………………………………………18 參考文獻………………………………………………………………………………32 | |
dc.language.iso | zh-TW | |
dc.title | 以噬菌體治療感染克雷白氏肺炎桿菌之小鼠 | zh_TW |
dc.title | Bacteriophage therapy in mice with infection caused by Klebsiella pneumoniae | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 楊宏志,董馨蓮,林稚容 | |
dc.subject.keyword | 克雷白氏肺炎桿菌,噬菌體療法,動物用核磁共振造影, | zh_TW |
dc.subject.keyword | Klebsiella pneumonia,phage therapy,animal MRI, | en |
dc.relation.page | 37 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-06-23 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 1.7 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。